Clinical Trials

A Multicenter Study of Sonablate 500 HIFU Treatment for Locally Recurrent Prostate Cancer: the STAR Trial

Protocol
09-164
Full Title
A Multicenter Clinical Study of the Sonablate® 500 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer with HIFU (STAR Trial)
Purpose

The goal of this study is to evaluate a therapy called high-intensity focused ultrasound (HIFU) to treat prostate cancers that have returned despite external beam radiation therapy. During HIFU, an ultrasound transducer — a wand-like device that emits high-intensity sound waves — is inserted into the rectum to destroy prostate tissue and cancer cells.

Investigator
James A. Eastham, MD, FACS -- Chief, Urology Service; Florence and Theodore Baumritter/Enid Ancell Chair of Urologic Oncology
James A. Eastham - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have T1c or T2 (nonmetastatic) prostate cancer that has returned two or more years following completion of external beam radiation therapy.
  • For patients who have had hormonal therapy, at least 90 days must have passed since completion of treatment and entry into the study.
  • Patients must be at least 40 years old but no older than 85.

For more information and to inquire about eligibility for this study, please contact Dr. James Eastham at 646-422-4390.

Disease(s)
Prostate Cancer
Prostate Cancer: Localized Disease
Prostate Cancer: Rising PSA After Primary Therapy
Locations
Related Diseases